Evaluating BHV-7000 for treating refractory focal onset epilepsy in adults
Official title: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Run by Biohaven Pharmaceuticals, Inc. · NCT06132893 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new treatment called BHV-7000 to see if it can help adults with difficult-to-treat focal onset epilepsy reduce their seizures.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 390 (estimated) |
| Sponsor | Biohaven Pharmaceuticals, Inc. Industry-sponsored |
| Locations | 124 sites (Phoenix, Arizona and 123 other locations) |
| Trial ID | NCT06132893 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with a diagnosis of refractory focal onset epilepsy who have failed multiple anti-seizure medications.
✕Probably not a fit
Patients with a history of status epilepticus or those who do not meet the criteria for refractory epilepsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the effectiveness and safety of BHV-7000 in adults suffering from refractory focal onset epilepsy. Participants will be administered either BHV-7000 or a placebo, with the goal of determining if this new treatment can help reduce seizure frequency. The study will include adults aged 18 to 75 who have a diagnosis of focal onset epilepsy and have not responded adequately to previous anti-seizure medications. Participants will be required to maintain accurate seizure diaries throughout the study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve seizure control for patients with refractory focal onset epilepsy.
How similar studies have gone: Other studies have explored treatments for refractory epilepsy, but the specific approach with BHV-7000 is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: 1. Male and Female participants 18 to 75 years of age at time of consent. 2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria. a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures iii. Focal to bilateral tonic-clonic seizures 3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. 4. Ability to keep accurate seizure diaries 5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total Key Exclusion Criteria: 1. History of status epilepticus (convulsive status epilepticus for \> 5 minutes or focal status epilepticus with impaired consciousness for \> 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure. 2. History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase. 3. Resection neurosurgery for seizures \<4 months prior to the screening visit. 4. Radiosurgery performed \<2 years prior to the screening visit. 5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms. 6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator
Where it's running
-
Barrow Neurological Institute
Phoenix, Arizona, United States Recruiting -
Center for Neurosciences
Tucson, Arizona, United States Recruiting -
Clinical Trials, Inc.
Little Rock, Arkansas, United States Recruiting -
University of California San Diego
La Jolla, California, United States Recruiting -
University of California, Los Angeles
Los Angeles, California, United States Recruiting -
Stanford Health Care
Palo Alto, California, United States Recruiting
Show 44 more locations
-
Profound Research LLC
Pasadena, California, United States Recruiting -
University of Colorado Anschultz Medical Campus
Aurora, Colorado, United States Recruiting -
Yale School of Medicine - Yale-New Haven Hospital
New Haven, Connecticut, United States Recruiting -
EZR Research LLC
Boca Raton, Florida, United States Recruiting -
Nova Clinical Research, LLC
Bradenton, Florida, United States Recruiting -
University of Florida (Jacksonville)
Jacksonville, Florida, United States Recruiting -
University of Miami
Miami, Florida, United States Recruiting -
Medsol Clinical Research Center
Port Charlotte, Florida, United States Recruiting -
Santos Research Center
Tampa, Florida, United States Recruiting -
Encore Medical Research of Weston LLC.
Weston, Florida, United States Recruiting -
Augusta University
Augusta, Georgia, United States Recruiting -
Hawaii Pacific Neuroscience
Honolulu, Hawaii, United States Recruiting -
Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States Recruiting -
Northwestern University
Chicago, Illinois, United States Recruiting -
Revive Research Institute, Inc.
Elgin, Illinois, United States Recruiting -
Bluegrass Epilepsy Research
Lexington, Kentucky, United States Recruiting -
Maesc
Bethesda, Maryland, United States Recruiting -
Minnesota Epilepsy Group, P.A.
Roseville, Minnesota, United States Recruiting -
Washington University School of Medicine
St Louis, Missouri, United States Recruiting -
Nereg
Hackensack, New Jersey, United States Recruiting -
Inst of Neurology
Livingston, New Jersey, United States Recruiting -
Dent Neurosciences Research Center
Amherst, New York, United States Recruiting -
Bchp
Hawthorne, New York, United States Recruiting -
Northwell Health
New York, New York, United States Recruiting -
Stony Brook Medicine
Stony Brook, New York, United States Recruiting -
Five Towns Neuroscience Research
Woodmere, New York, United States Recruiting -
Wake Forest Baptist
Winston-Salem, North Carolina, United States Recruiting -
NeuroScience Research Center
Canton, Ohio, United States Recruiting -
University of Cincinnati
Cincinnati, Ohio, United States Recruiting -
Osu
Columbus, Ohio, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
Thomas Jefferson University
Philadelphia, Pennsylvania, United States Recruiting -
Upmc
Pittsburgh, Pennsylvania, United States Recruiting -
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting -
Neurology Consultants of Dallas, PA
Dallas, Texas, United States Recruiting -
UT Health San Antonio
San Antonio, Texas, United States Recruiting -
Road Runner Research, Ltd
San Antonio, Texas, United States Recruiting -
University of Utah
Salt Lake City, Utah, United States Recruiting -
University of Virginia
Charlottesville, Virginia, United States Recruiting -
Henrico Doctors Neurology Associates, LLC
Richmond, Virginia, United States Recruiting -
Carilion Clinic
Roanoke, Virginia, United States Recruiting -
STAT Research S.A.
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina Recruiting -
Hospital General de Agudos Dr. José María Ramos Mejia
Balvanera, Ciudad Autónoma de BuenosAires, Argentina Recruiting -
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno CEMIC-Elías Galván 4102
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina Recruiting
+74 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Chief Medical Officer
- Email: clinicaltrials@biohavenpharma.com
- Phone: 203-404-0410
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-density flexible microneuroelectrode mapping to guide epilepsy surgery
This study tests whether using high-density flexible microelectrocorticography during surgery helps guide the resection of the epileptogenic zone in people with drug-resistant focal epilepsy.
-
RAP-219 for adults with focal seizures
This study tests whether RAP-219 can reduce how often focal seizures happen in adults with focal epilepsy, compared with a placebo.
-
Spatial scene memory testing for people with temporal lobe epilepsy having surgery
This project tests whether a virtual tour memory task combined with brain recordings can show how adults with temporal lobe epilepsy recognize and recall places.
-
RAP-219 in adults with focal seizures
This study tests whether RAP-219 can safely reduce the number of focal seizures in adults with focal epilepsy compared with placebo.
-
Probenecid for cluster seizures during presurgical epilepsy monitoring
This trial tests whether probenecid can help control clusters of seizures in people with focal epilepsy during presurgical video-EEG monitoring.
-
Long-term daily CB03-154 treatment for focal epilepsy
This extension will try once-daily CB03-154 (up to 20 mg) in people with focal epilepsy who completed the prior Phase 2 study to see if it is safe, tolerated, and helps control seizures over up to two years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.